High dose celecoxib (C) and docetaxel (D) in patients (pts) with hormone resistant prostate cancer (HRPC). Results of an ongoing phase II trial.

被引：0
|
作者：
Kasimis, B
Cogswell, J
Hwang, S
Chang, VT
Srinivas, S
Zhong, F
Duque, L
Morales, E
Boholli, I
Blumenfrucht, M
机构：
[1] VA NJ Hlth Care Syst, E Orange, NJ USA
[2] VA New Jersey Hlth Care Syst, E Orange, NJ USA
[3] Univ Med & Dent New Jersey, VA New Jersey Hlth Care Syst, E Orange, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：428S / 428S
页数：1
相关论文
共 50 条
  • [31] Docetaxel and Curcuminoids Combination In Patients With Hormone Resistant Prostate Cancer - a Phase II Study
    Mahammedi, H.
    Planchat, E.
    Durando, X.
    Barthomeuf, C.
    Bayet-Robert, M.
    Van-Praagh, I.
    Francannet, P.
    Guy, L.
    Chollet, P.
    Eymard, J. C.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S498 - S498
  • [32] Phase II clinical trial of metronomic cyclophosphamide (CTX) plus celecoxib (C) and dexamethasone (DEX) in advanced hormone refractory prostate cancer (HRPC): Preliminary clinical and pharmacodynamic results
    Fontana, A.
    Bocci, G.
    D'Arcangelo, M.
    Galli, L.
    Fontana, E.
    Galli, C.
    Landi, L.
    Fioravanti, A.
    Orlandi, P.
    Barletta, M.
    Marsico, R.
    Barsanti, G.
    Andreuccetti, M.
    Del, Tacca M.
    Falcone, A.
    ANNALS OF ONCOLOGY, 2007, 18 : 82 - 82
  • [33] Phase II study of CC-4047 in patients (pts) with metastatic hormone-refractory prostate cancer (HRPC)
    Floissac, M
    Knight, R
    Levin, A
    Glode, LM
    Crawford, ED
    Amato, RJ
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 410S - 410S
  • [34] Phase III trial of docetaxel (D), estramustine (E), and prednisone versus docetaxel plus prednisone in patients with metastatic hormone-refractory prostate cancer (HRPC)
    Machiels, J. H.
    Mazzeo, F.
    Clausse, M.
    Filleul, B.
    Marcelis, L.
    Honhon, B.
    D'Hondt, L.
    Dopchie, C.
    Bonny, M.
    Kerger, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [35] Dose finding and safety analysis of inecalcitol in combination with docetaxel-prednisone regimen in hormone-refractory prostate cancer (HRPC) patients (pts)
    Medioni, J.
    Deplanque, G.
    Maurina, T.
    Ferrero, J. M.
    Rodier, J. M.
    Raymond, E.
    Allyon, J.
    Kalla, S.
    Dufour-Lamartinie, J. F.
    Oudard, S.
    EJC SUPPLEMENTS, 2009, 7 (02): : 415 - 415
  • [36] High efficacy of carboplatin (C) plus weekly docetaxel (D) as second-line treatment for docetaxel-resistant, hormone-refractory prostate cancer (HRPC)
    Reuter, C. W. M.
    Morgan, M.
    Fenner, M.
    Winkler, T.
    Ganser, A.
    Gruenwald, V.
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2009, 72 : S39 - S39
  • [37] A phase II trial of docetaxel and vinorelbine in patients with hormone-refractory prostate cancer
    Goodin, S
    Rao, KV
    Kane, M
    Dave, N
    Capanna, T
    Doyle-Lindrud, S
    Engle, E
    Jin, LX
    Todd, M
    DiPaola, RS
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2005, 56 (02) : 199 - 204
  • [38] A phase II trial of docetaxel and vinorelbine in patients with hormone-refractory prostate cancer
    Susan Goodin
    Kamakshi V. Rao
    Michael Kane
    Nisha Dave
    Terry Capanna
    Susan Doyle-Lindrud
    Elizabeth Engle
    Lixian Jin
    Mary Todd
    Robert S. DiPaola
    Cancer Chemotherapy and Pharmacology, 2005, 56 : 199 - 204
  • [39] Second line chemotherapy with estramustine (E) plus docetaxel(D) in patients with hormone-refractory prostate cancer (HRPC), resistant to docetaxel alone
    Caffo, Orazio
    Sava, Teodoro
    Comploj, Evi
    Segati, Romana
    Giampaolo, Marianna
    Valduga, Francesco
    Caldara, Alessia
    Galligioni, Enzo
    ANNALS OF ONCOLOGY, 2007, 18 : 70 - 70
  • [40] Phase II trial of bevacizumab (A), lenalidomide (R), docetaxel (D), and prednisone (P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
    Huang, X.
    Ning, Y. M.
    Mulquin, M.
    Madan, R. A.
    Gulley, J. L.
    Kluetz, P. G.
    Adelberg, D.
    Arlen, P. M.
    Parnes, H. L.
    Adesunloye, B.
    Steinberg, S. M.
    Wright, J. J.
    Trepel, J. B.
    Chen, C.
    Bassim, C.
    Apolo, A. B.
    Figg, W. D.
    Dahut, W. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345